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Stable transgenic C9orf72 zebrafish model
key aspects of the ALS/FTD phenotype and
reveal novel pathological features
Matthew P. Shaw1, Adrian Higginbottom1, Alexander McGown1, Lydia M. Castelli1, Evlyn James1,
Guillaume M. Hautbergue1, Pamela J. Shaw1† and Tennore M. Ramesh1,2*†
Abstract
A hexanucleotide repeat expansion (HRE) within the chromosome 9 open reading frame 72 (C9orf72) gene is the most
prevalent cause of amyotrophic lateral sclerosis/fronto-temporal dementia (ALS/FTD). Current evidence suggests HREs
induce neurodegeneration through accumulation of RNA foci and/or dipeptide repeat proteins (DPR). C9orf72
patients are known to have transactive response DNA binding protein 43 kDa (TDP-43) proteinopathy, but
whether there is further cross over between C9orf72 pathology and the pathology of other ALS sub-types has
yet to be revealed.
To address this, we generated and characterised two zebrafish lines expressing C9orf72 HREs. We also characterised
pathology in human C9orf72-ALS cases. In addition, we utilised a reporter construct that expresses DsRed under the
control of a heat shock promoter, to screen for potential therapeutic compounds.
Both zebrafish lines showed accumulation of RNA foci and DPR. Our C9-ALS/FTD zebrafish model is the first
to recapitulate the motor deficits, cognitive impairment, muscle atrophy, motor neuron loss and mortality in
early adulthood observed in human C9orf72-ALS/FTD. Furthermore, we identified that in zebrafish, human cell
lines and human post-mortem tissue, C9orf72 expansions activate the heat shock response (HSR). Additionally,
HSR activation correlated with disease progression in our C9-ALS/FTD zebrafish model. Lastly, we identified
that the compound ivermectin, as well as riluzole, reduced HSR activation in both C9-ALS/FTD and SOD1
zebrafish models.
Thus, our C9-ALS/FTD zebrafish model is a stable transgenic model which recapitulates key features of human
C9orf72-ALS/FTD, and represents a powerful drug-discovery tool.
Keywords: Amyotrophic lateral sclerosis, C9orf72, SOD1, TDP-43, Zebrafish, Drug-screening
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disorder characterised by motor neuron loss, leading to
progressive muscle weakness and eventual death, primar-
ily due to respiratory failure. Approximately 10% of ALS is
inherited in an autosomal dominant fashion, this is known
as familial-ALS (fALS). The remaining 90% of ALS cases
are caused by complex genetic and environmental
interactions which are currently not well understood, this
is known as sporadic-ALS (sALS). Mutations in multiple
genetic loci have been identified as causes of ALS includ-
ing the SOD1 and TARDBP loci. See Amyotrophic Lateral
Sclerosis Online Genetics Database for comprehensive
information (http://alsod.iop.kcl.ac.uk/). The most com-
mon known genetic cause of ALS and frontotemporal de-
mentia (FTD) is a hexanucleotide expansion within the
first intron of the C9orf72 gene [11, 32]. Carriers of the
C9orf72 hexanucleotide expansion may show symptoms
of ALS or FTD exclusively, but can also present with
symptoms of both diseases concurrently.
Concerning pathology in C9orf72 patients, there are three
major, non-mutually exclusive routes of toxicity which have
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been proposed to arise from the C9orf72 expansion: 1)
Sense and antisense RNA foci which sequester RNA bind-
ing proteins causing dysregulation of RNA processing
[7, 11]. 2) Dipeptide repeat proteins (DPRs) produced
via non-canonical repeat associated non-ATG (RAN)
translation, form insoluble aggregates in the nucleus
and cytoplasm [42]. 3) Hexanucleotide expansion medi-
ated haploinsufficiency may cause dysregulation of en-
dogenous C9orf72 pathways such as autophagy [12, 39].
To date, several models have been generated to help
dissect out the mechanisms of C9orf72 expansion medi-
ated toxicity. Most drosophila and zebrafish models sup-
port an RNA/DPR mediated gain of toxic function
hypothesis [18, 26, 28, 37]. In addition, transgenic mouse
models have been generated containing the human
patient C9orf72 gene (complete with G4C2 expansion
and flanking regions). Two transgenic mouse models
demonstrate the reduced survival, neuronal loss and
motor deficits observed in human C9-ALS/FTD [14, 20].
However, a further two independently generated C9orf72
transgenic models showed no signs of neuronal loss or
reduced survival. [29, 30]. This highlights the wide vari-
ability observed in C9orf72 expansion in vivo models.
C9orf72 knockdown in the zebrafish causes mild motor
defects [6]. However, early reports from C9orf72 knock-
out zebrafish do not recapitulate the knockdown motor
phenotypes ([34]; Schmid, Hruscha, Haass, unpublished).
Additionally, four independently generated C9orf72
knockout mice did not demonstrate any neurodegenera-
tive phenotype [1, 13, 17, 35].
Whilst mouse models are a useful tool for understand-
ing the pathobiology of C9orf72-related ALS, they are
not amenable to high throughput drug screening. Gen-
etic modifier screens have been carried out in drosoph-
ila, but their CNS is much simpler compared to the
human CNS and findings in this invertebrate model are
less likely to translate to the clinic [3, 15]. Zebrafish are
vertebrates with a more complex CNS, and therefore
represent a practical compromise for assessing the effi-
cacy of therapeutic compounds.
Here we present a novel transgenic zebrafish model
which stably expresses C9orf72 expansions. These zeb-
rafish recapitulate the behavioural deficits, cognitive ab-
normalities, motor decline and early mortality observed
in C9-ALS patients. Additionally we show that C9orf72
expansions activate the heat shock response in human
cell lines, post-mortem ALS tissue and our model zeb-
rafish. Using these C9orf72 zebrafish and our previously
reported SOD1 zebrafish in tandem [31], we show that
riluzole and a newly identified compound, ivermectin,
are able to reduce cellular stress in both C9orf72 and
SOD1 in vivo models. We therefore propose that our
C9orf72 zebrafish model effectively bridges the gap
between drosophila and mouse models by providing an
efficient tool for high-throughput in vivo drug screen-
ing assays.
Materials and methods
Generating and maintenance of transgenic zebrafish
Zebrafish embryos were injected with a DNA construct
containing 89 C9orf72 hexanucleotide repeats driven by a
zebrafish ubiquitin promotor (Fig. 1a, Additional file 1).
Creation and identification of transgenic zebrafish was
performed as previously described [31] and maintained
using established practices [40].
In situ hybridisation and immunofluorescence
In situ hybridization of paraffin embedded tissue sec-
tions to detect CCCCGG (C4G2) foci was performed on
5dpf embryos using methods described previously [8].
For immunofluorescence staining, paraffin embedded
tissue was dewaxed, antigen retrieved and stained as
previously described [9].
Western blotting
Ethical approval for use of human cerebellum samples
was obtained by the Sheffield Brain Tissue Bank Manage-
ment Board, and approval to release tissue under REC 08/
MRE00/103 was granted. Human cerebellum samples and
adult zebrafish tissue, brain, spinal cord and whole zebra-
fish embryos were snap frozen in liquid nitrogen and
processed for western blotting. Laemmli buffer was added
in the ratio of 10 μl:1 mg of tissue and sonicated. SDS-
PAGE and immunoblotting were performed as previously
described [39]. Antibodies used were Rb-anti-PR (gift
from Dieter Edbauer), Rb-anti-Dsred (Clontech 632,496),
Ms-anti-tubulin (Abcam). Species specific HRP conju-
gated secondary antibodies were used and imaged by
chemiluminescence using G-Box.
Embryonic behaviour
For spontaneous locomotor activity, 5 dpf zebrafish were
placed into individual wells of a 96well plate and habituated
in the dark for 10 min before a light stimulus was turned
on. 10 min of light was followed by 10 min dark and
repeated once more. Recordings were carried out using
ZebraBox software (ViewPoint Behaviour Technologies),
movement thresholds used were slow (x < 5 mm/sec),
intermediate (5 < x < 15 mm/sec) and fast (x > 15 mm/sec).
For centre avoidance behaviour, 5 dpf zebrafish were
placed into a 6 well plate at a density of 30 zebrafish per
well. After a 30 min habituation period with the lights
on, the lights were turned off for 5 min then on for
5 min for 6 cycles. Frame grab was performed at 30 s for
every minute in the lights on condition using the Image-
grab tool, and this was repeated for each of the 6 lights
on periods. Using ImageJ, circles of the same size were
placed around the outside of every well so that only the
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centre of the well was visible, the % of zebrafish present
in the centre of the well was then blind counted for
every image and the average per well was calculated.
Adult locomotor behaviour
Zebrafish swimming ability was tested using a swim tun-
nel with an intial flow-rate of 2 L/min, increasing in 2 L/
min increments every 5 min until the maximum flow rate
of 11.6 L/min was achieved. Data were analysed as previ-
ously described [31]. 5 min post-testing, the spontaneous
swimming behaviour of the fish was measured for 30 min
using a camera linked to ZebraLab software (ViewPoint
Behaviour Technologies). Speed thresholds used were
slow (x < 60 mm/sec), intermediate (60 < x < 120 mm/sec)
and fast (x > 120 mm/sec).
Motor neuron counts and myotome measurements
Spinal motor neurons were counted from paraffin em-
bedded adult zebrafish segments cut anterior to the
pelvic fin, sectioned at 10 μm and stained with haema-
toxylin and eosin. Cells with a soma size >75μm2 and
within 25,000μm2 proximity of the central canal were
designated as motor neurons. Three sections/per animal
were analysed by two independent blinded investigators
and averaged. The areas of individual myotomes were
measured by a blinded investigator from 6 images per
animal. All muscle images were obtained from the ep-
axial muscle region just lateral to the dorsal spinal bone.
Any myotome which was incomplete due to being par-
tially out of frame was not included in the analysis.
Cell culture and transfections
Cells were maintained in a 37 °C incubator with 5% CO2.
HEK293T cells were cultured in Dulbecco’s Modified
Eagle Medium (Sigma) supplemented with 10% foetal bo-
vine serum (FBS) (Gibco) and 5 U ml− 1 Penstrep (Lonza).
Neuro-2a(N2A) (ATCC) cells were cultured in Dulbecco’s
Modified Eagle Medium (Sigma) supplemented with 10%
FBS (Gibco), 5 U ml− 1 Penstrep (Lonza) and 5 mM so-
dium pyruvate.
HEK293T and N2A cells were transfected with 700 ng of
plasmid using 3.5 μg PEI/ml media and one tenth media
volume of OptiMEM in a 24 well format. Approximately,
50,000 HEK293T cells were seeded / well and 75,000 N2A
cells were seeded per well of the 24 well plate. Proteins
were extracted 72 h post-transfection. Cells were washed in
Fig. 1 C9orf72 model zebrafish display RNA foci in the nucleus. (a) Schematic representation of the transgene inserted into 2.2 zebrafish. A
zebrafish ubiquitin promotor drives GFP-DPR expression. An hsp70 promotor then drives DsRed production as a read out of cellular stress.
(b) In situ hybridisation of paraffin embedded sections of 10dpf 2.2–7 zebrafish using a Cy3-conjugated (red) GC probe (GGGGCC)X4 showed
that RNA foci are present in the nuclei of muscle cells. Arrow heads denote RNA foci. Scale bar = 10 μm. (c) Quantification of RNA foci showed
Immunofluorescence labelling of adult zebrafish muscle tissue showed that poly-GP DPR protein localises to the nucleus in 2.2–2 and 2.2–7
transgenic zebrafish
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ice cold phosphate buffered saline (PBS) and subsequently
lysed in ice cold lysis buffer (50mM Hepes pH 7.5, 150
mM NaCl, 10% glycerol, 0.5% Triton X-100, 1mM EDTA,
1mM DTT, protease inhibitor cocktail (Sigma)) for
10 min on ice. Extracts were then centrifuged at 17,000 g
for 5 min at 4 °C. Extracts were quantified using Bradford
Reagent (BioRAD), resolved by SDS-PAGE, electroblotted
onto nitrocellulose membrane and probed to the relevant
primary antibodies.
Heat shock cell stress drug screening assay
At 2 dpf, transgenic zebrafish were placed into a 96 well
plate in 200 μl of drug or DMSO containing E3 zebrafish
media. At 5 dpf zebrafish were sonicated in the well for
10 s each and then centrifuged in a plate spinner at
3000 rpm for 10 min. From each well, 20 μl of super-
natant was transferred into a 385 well plate, and the
DsRed levels in each individual lysate were quantified
using a FLUOstar Omega fluorescence plate reader
(BMG labtech).
Quantification and statistical analysis
Data were analysed by one way ANOVA with Tukey’s post
hoc test or two way ANOVA with Sidak’s post hoc test for
multiple comparisons, t-test or Kaplan Meier analysis as in-
dicated in the appropriate figure legend. Significance is
denoted as * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P <
0.0001. Individual myotome size data were counted into bins
with a 0.5mm2 size range. The frequency distribution of
each genotype was then compared using a chi-squared test
for trend.
Results
Generation of transgenic zebrafish
To better understand ALS/FTD pathogenesis and screen
potential therapeutic agents, we generated a C9orf72 zeb-
rafish model. At the single cell stage zebrafish embryos
were injected with a DNA construct containing 89
C9orf72 hexanucleotide repeats (Fig. 1a, Additional file 1).
Of the 3 zebrafish lines generated, one was extremely
toxic, resulting in death within 7 days of fertilisation (dpf).
Therefore, only the 2 remaining lines were maintained to
breeding age and established for further characterisation.
These two transgenic zebrafish lines which were estab-
lished to adulthood will henceforth be known as line 2.2–
2 and line 2.2–7, or collectively as 2.2-zebrafish lines. Both
2.2-zebrafish lines give rise to 1:1 ratios of transgenic:NTG
offspring when outbred, suggesting a single site of trans-
gene insertion.
C9orf72 zebrafish lines express RNA foci and DPR
The hallmark features of C9orf72 pathology are expression
of RNA foci and DPR species. Using in situ hybridisation
and immunofluorescence, we identified expression of
RNA foci and DPR species in both 2.2-zebrafish lines.
Antisense RNA foci (CCCCGG, the same orientation with
respect to the construct) can be detected in the nuclei of
muscle cells in both 2.2-zebrafish lines (Fig. 1b), no more
than one focus is observed per nucleus, and no cytoplas-
mic foci were detected. 50% (11/22) of nuclei in 2.2.7 line
showed RNA nuclear foci while fewer foci (30%, 6/20)
were observed in 2.2.2 line. Non-transgenics showed 4%
(1/25) foci like staining but failed to show colocalisation in
the nuclei (Fig. 1c). It is presumed, that the single focus
observed in the NTG zebrafish was due to non-specific
binding of the in situ probe. To determine whether repeat
RNA was translated into DPR proteins, antibodies specific
to antisense DPR species poly-GP, PA and PR were used.
All three antisense DPR species were detected in the
nuclei of muscle cells from both 2.2-zebrafish lines
(Fig. 2a,c,e) with over 50% of the nuclei expressing the
DPRs (Fig. 2b,d,f).
C9orf72 zebrafish produce multiple distinct DPR species
The various DPR species are known to have differential
toxicity, with arginine rich species being considered the
most toxic. To investigate whether there is a relationship
between molecular weight (MW) and species toxicity,
western blotting was performed on zebrafish lysates. The
transgene construct expressed in both 2.2-zebrafish lines
causes the production of GFP tagged DPR proteins via
canonical ATG (start codon) dependent translation. The
full length GFP fusion protein is predicted to be 48 kDa
while any truncation 3′ of any C4G2 repeats would re-
sult in the production of GFP alone (28KDa). The sche-
matic of the GFP-DPR fusion protein is shown (Fig. 3a).
GFP tagged DPRs are produced from C4G2 transcripts
and can be detected at 5 dpf (Fig. 3b, left most panel).
Interestingly, multiple GFP bands are detected in both
the 2.2–2 and 2.2–7 zebrafish lines, and these bands
were often unique to one zebrafish line or the other, and
were consistent over > 10 clutches. The differential ex-
pression of DPRs between 2.2–2 and 2.2–7 zebrafish
also holds true when probing for the DPR proteins dir-
ectly (Fig. 3b, 3 right panels). The full length GFP-DPR
fusion at 48 kDa was expressed but at low levels
(Fig. 3b, 48 kDa band). Probing antibodies against DPR
proteins also revealed that some DPR bands detected did
not co-localise with any of the ATG-dependent translation
bands detected using the GFP antibody, suggesting that
these bands are likely to be produced via non-canonical
RAN translation (Fig. 3b, three right panels marked
with asterix).
In addition to the poly-PA, PR and GP DPRs produced
from the (C4G2) RNA transcripts, we were also able to de-
tect poly(GA) DPR produced from the (G4C2) RNA tran-
script, however poly(GA) was only detected in the 2.2–7
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zebrafish line (Fig. 3c). The detection of poly(GA) indi-
cates that bidirectional transcription of the GC rich region
is occurring in the presence of our transgene. As the tran-
scription of the RNA transcript containing the (G4C2) ex-
pansion is not driven by a conventional promotor region,
this strongly indicates that poly(GA) protein is indeed pro-
duced via RAN translation.
In human ALS, C9orf72 associated toxicity occurs
primarily in cells of the CNS, and so it is essential to
ascertain whether DPR species are also produced
within the CNS of this C9orf72 model zebrafish. In
adult brain and spinal cord of both 2.2-zebrafish lines,
GFP-tagged DPR species and DPR species which were
not immunoreactive with GFP antibodies (RAN trans-
lation bands), could be detected (Fig. 4). This suggests
that both ATG-dependent translation and RAN trans-
lation of DPR species occurs within the CNS of the
2.2-zebrafish.
In summary, both 2.2-zebrafish lines exhibit DPR species
generated by conventional ATG-dependent translation and
RAN translation in the muscle and the CNS. In addition,
the 2.2–7 zebrafish line shows bi-directional transcription,
producing DPR species from both G4C2 and C4G2 RNA
transcripts. In both 2.2-zebrafish lines, the band pattern of
DPRs detected largely remains constant from 5 dpf until
adulthood, although higher MW (>50KDa) poly(PR) posi-
tive bands are more abundant in adult tissue. Of all the
DPR species examined here, poly(PR) generally has the
highest propensity to form high MW RAN-translation
mediated bands.
Fig. 2 C9orf72 model zebrafish display DPR expression in the nucleus. (a,b) Immunofluorescence labelling of adult zebrafish muscle tissue
showed that poly-GP DPR protein localises to the nucleus in 2.2–2 and 2.2–7 transgenic zebrafish. (c.d) Immunofluorescence labelling of adult
zebrafish muscle tissue showed that poly-PA DPR protein localises to the nucleus in 2.2–2 and 2.2–7 transgenic zebrafish. (e,f) Immunofluorescence
labelling of adult zebrafish muscle tissue showed that poly-PA DPR protein localises to the nucleus in 2.2–2 and 2.2–7 transgenic zebrafish. For all DPR
images nuclei are stained with Hoechst (blue), GFP is stained with GFP antibody (green) and DPR proteins are stained with the relevant DPR antibody
(purple), white arrow heads denote DPR positive staining. Scale bar = 25 μm for all DPR images
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Early mortality, altered swimming behaviour and reduced
weight gain in transgenic C9orf72 zebrafish
Neither 2.2-zebrafish lines showed any overt morpho-
logical abnormalities during embryonic development (0–
5 dpf ). At 5 dpf zebrafish begin to express a wider reper-
toire of behaviours, including more frequent swimming
and independent feeding. For this reason, rigorous
evaluation was performed on 5 dpf zebrafish to test for
underlying motor and behavioural deficits. In order to
test the spontaneous locomotor activity of embryonic
zebrafish, we monitored 5 dpf zebrafish in 96 well plates
using the Viewpoint behaviour monitoring setup. No sig-
nificant difference was observed between the groups in
the proportion of times transitioning occurred into slow
or medium movements (Fig. 5a). However, a significant
reduction in the proportion of transitions into fast
movement was detected in 2.2–7 zebrafish, when com-
pared to either NTG or 2.2–2 zebrafish (Fig. 5a).
As C9orf72 expansions in human ALS cause a spectrum
of both motor and cognitive deficits, we examined
whether normal zebrafish behaviour was affected in
2.2–7 zebrafish at 5 dpf. Centre avoidance behaviour
assays are a validated means of measuring willingness
to explore in zebrafish [33], and are comparable to the
open field test performed in mice. It was determined
that 2.2–7 zebrafish were significantly less likely to ven-
ture into the centre of the well when compared to their
NTG clutchmates (Fig. 5b+c).
To determine if the early embryonic expression of
RNA foci and DPR impacted upon the viability of the
C9orf72 zebrafish, we carried out early (1–15 dpf) sur-
vival analysis. Heterozygous 2.2–2 zebrafish do not show
any change in survival within 15 dpf as compared to
NTG zebrafish (data from NTG clutchmates of all geno-
types are pooled; Fig. 5d). However, heterozygous 2.2–7
zebrafish did show a significant decrease in survival
within 15 dpf as compared to NTG zebrafish (Fig. 5d),
but not in comparison to 2.2–2 zebrafish.
It was noted that during early development, the 2.2–7
zebrafish appeared smaller than their NTG clutchmates.
At 30 dpf there was a significant decrease in total body
weight of 2.2–7 zebrafish compared to their NTG
Fig. 3 C9orf72 model zebrafish produce multiple species of DPRs from sense and anti-sense transcripts (a) Schematic of the GFP-DPR
fusion protein produced by AUG driven translation. (b) Anti-sense DPRs (predominately ATG-driven) containing full length-GFP-DPR fusion,
intermediate GFP-DPR fusion and GFP alone bands are detected in 5dpf embryonic lysates. Non-AUG driven GFP deficient RAN translation
DPR are also detected in both 2.2.2 and 2.2.7 transgenic lines (Asterix) (C) Sense Poly(GA) DPRs (exclusively RAN-translation driven)
detected in 5dpf embryonic lysates
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clutchmates (Fig. 5e). However, 2.2–2 zebrafish did not
show a significant difference in body weight as compared
to their own clutchmates at the same age (Fig. 5f).
In summary, 2.2–7 zebrafish but not 2.2–2 zebrafish,
show significant reduction in survival at 15 dpf, and
reduction in bodyweight at 30 dpf. At 5 dpf, 2.2–7 zeb-
rafish also show defects in swimming activity and dis-
played signs of atypical behaviour. Behaviour of the
phenotypically more severe 2.2–7 zebrafish was also
studied through adulthood.
C9orf72 zebrafish display adult onset ALS-like behavioural
phenotypes
To assess the neuro-muscular integrity of the 2.2–7 trans-
genic zebrafish, swimming endurance was tested using a
swim tunnel, the aquatic equivalent to a treadmill [31]. At
9 months of age more 2.2–7 transgenic zebrafish failed to
maintain swimming at the maximum flow rate as com-
pared with their NTG clutchmates (Fig. 6a). Despite de-
creased body mass during early development, body mass
and body size were not significantly different between adult
transgenic and NTG groups from 9 months of age
(Additional file 2: Figure S1). Spontaneous swimming was
observed immediately following swim tunnel testing, but
no difference was observed between the two groups
(Fig. 6d). The swim tunnel test was repeated with the
same cohort of zebrafish at 12 months of age, and the
ability to swim at maximum speed continued to decrease
in the 2.2–7 zebrafish (Fig. 6b). Interestingly, at 12 months
2.2–7 zebrafish now showed defects in spontaneous swim-
ming behaviour following the swim tunnel testing.
12-month-old zebrafish showed an increase in the propor-
tion of times transitioned into slow speed movements and
a concomitant decrease in the proportion of times transi-
tioned into fast speed movement, as compared to NTG
clutchmates at the first-time point following swim tunnel
testing (Fig. 6e).
Adult survival was also monitored from 8 months post-
fertilisation onwards. By 17 months post-fertilisation, sur-
vival rates of the 2.2–7 transgenic zebrafish were signifi-
cantly reduced in comparison to their NTG clutchmates
(44% vs 100% survival respectively; Fig. 6c). A zebrafish
was defined as having reached end-stage once it had lost
the ability to maintain normal swimming (showing signs
of paralysis) to the extent where it was no longer able to
obtain food. End-stage 2.2–7 zebrafish displayed severe
wasting in the body muscle region and had very poor
locomotor skills (Additional file 3: video 1, no NTG zebra-
fish displayed this wasting phenotype.
Muscle atrophy and motor neuron loss in C9orf72
zebrafish
Progressive muscle atrophy is observed in all ALS pa-
tients. Similarly, end-stage 2.2–7 zebrafish muscle dis-
played widespread severe atrophy, muscle fibres were
disorganised, and a large increase in nuclei was observed
(Fig. 7a). The muscle of 2.2–2 zebrafish displayed more
subtle changes, with myotomes being significantly smaller
Fig. 4 C9orf72 model zebrafish produce multiple species of DPRs in the adult CNS. (a) Anti-sense DPRs (predominately ATG-driven) detected in
adult brain lysates. (b) Anti-sense DPRs (predominately ATG-driven) detected in adult spinal cord lysates. Asterix (*) denotes protein bands which
are proposed to have been produced via RAN-translation
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and more numerous as compared to NTG muscle (Fig. 7a
+b). We did not quantify end-stage 2.2–7 zebrafish muscle
fibre size, as their myofibres were too disorganised to dis-
cern individual myotomes.
In ALS patients, the underlying molecular pathology
ultimately leads to motor neuron death. Similarly, sig-
nificant loss of ventral horn motor neurons was ob-
served in end-stage 2.2–7 zebrafish as compared with
NTG controls (Fig. 7c+d). A small, non-significant
reduction in motor neurons was observed in 2.2–2 zeb-
rafish as compared with NTG controls.
Heat shock stress response is activated by C9orf72
expansions
Heat shock proteins are upregulated in response to the
presence of aberrant cellular proteins [4, 10]. We hypothe-
sised that the low-complexity structure of DPR proteins
might drive activation of the heat shock response (HSR).
Fig. 5 C9orf72 model zebrafish show early motor deficits, behavioural defects and reduced viability. (a) When kept under dark conditions, no
difference is observed in the proportion of times fish transition into a slow movement (left) or intermediate movement (middle). However, the
proportion of transitions into fast movements is significantly reduced in 2.2–7 zebrafish. N = 60 individual fish per genotype, from 3 different
clutches. (b) Representative images of the plate set-up used to monitor centre avoidance behaviour in zebrafish. 30 fish were placed in each well
and one image every minute was analysed. Image shown as recorded (top) and then following removal of the region around the edge of the
plate for analysis (bottom). In these images 2.2–7 are placed across the top 3 wells and NTG across the bottom 3 wells. (c) Quantification of
centre avoidance behaviour showing 2.2–7 zebrafish are significantly less often found in the plate centre. N = 6 clutches per genotype. (d)
Survival of zebrafish did not change by 5dpf, however by 15dpf survival of the 2.2–7 line was significantly reduced compared to NTG. N = 4
clutches per genotype. (e) At 30dpf 2.2–7 zebrafish have reduced average body weight in comparison to their NTG clutch mates. N = 3 clutches
per genotype. (f) At 30dpf there was no difference in average body weight between 2.2–2 zebrafish and their NTG clutch mates. N = 3 clutches
per genotype. All data are shown as mean +/− standard deviation; *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
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To test this, we transfected both HEK 293 T and N2A
cells with C9orf72 expansion containing pure HRE and
interrupted HRE constructs. The repeats were expressed
in tandem with a hsp70 promotor driving a DsRed gene,
as a readout of heat shock response activation. As DsRed
is more stable than hsp70, it allows more sensitive detec-
tion of small but chronic HSR activation [24]. In both
HEK and N2A cells, cells transfected with 39 C4G2 pure
repeats (left two panels) or 89 interrupted repeats (right
sided panel) showed strong RAN-translated V5-tagged
DPR or ATG driven PR-tagged DPR production and
markedly higher DsRed production (Fig. 8a). In contrast,
cells transfected with only 2 C4G2 repeats displayed no
RAN-translated DPRs and less or undectable DsRed pro-
duction. As expected cells transfected with 39 C4G2 re-
peats but no hsp70:DsRed heat shock readout, produced
abundant RAN-translated DPRs but no DsRed protein.
To assess differences in HSR activation in the more
phenotypically severe 2.2–7 zebrafish vs the less severe
2.2–2 zebrafish, we screened 5 dpf zebrafish for DsRed
(produced via hsp70 promotor activation). The more severe
2.2–7 zebrafish showed significantly increased DsRed
Fig. 6 C9orf72 model zebrafish show adult onset swimming endurance deficits and reduced survival. (a) At nine months old, 2.2–7 transgenic
zebrafish failed to continue swimming at earlier time points than their NTG clutch mates. N = 13 fish per genotype. (b) Also at twelve months old,
2.2–7 transgenic zebrafish failed to continue swimming at earlier time points than their NTG clutch mates. N = 13 fish per genotype. (c) Adult
transgenic 2.2–7 zebrafish have reduced survival between 8 and 17 months in comparison to their NTG clutch mates which are housed in the
same tank. N = 17 2.2–7 and 27 NTG at 8 months. (d) After being removed from the swim tunnel, 9 month old fish did not show any significant
difference in proportion of transitions into slow (left), intermediate (middle) or fast (right) movements. N = 12 fish per genotype. (e) After being
removed from the swim tunnel, 12 month old 2.2–7 zebrafish showed a significant increase in the proportion of transitions into slow movements
and a corresponding significant decrease in the proportion of transitions into fast movement. There was no change in transition into intermediate
movement. N = 13 fish per genotype. All data are shown as mean +/− standard deviation; *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
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fluorescence in comparison to 2.2–2 zebrafish at 5dpf (Fig.
8b). Importantly, GFP fluorescence (from GFP-tagged
DPRs) was not significantly different between 2.2–7 and
2.2–2 zebrafish (Fig. 8c).
To assess how HSR activation changes as phenotypic
severity increases, we examined GFP and DsRed produc-
tion in adult zebrafish brains, from 3 end-stage 2.2–7
zebrafish (ages 15, 15 and 19 months), 3 pre-symptomatic
2.2–7 zebrafish (all aged 7 months) and 3 NTG zebrafish
(age matched to end-stage). Pre-symptomatic was defined
as fish which did not show any overt swimming or muscle
abnormalities. GFP tagged DPRs were increased in the
brains of end-stage zebrafish in comparison to the brains
of pre-symptomatic zebrafish (Fig. 8d+e). Similarly, DsRed
also increased in the brains of end-stage zebrafish in
comparison to the brains of pre-symptomatic zebra-
fish (Fig. 8d+f ), thus suggesting an association be-
tween DPR production and HSR induction.
Finally, we examined whether HSR activation could
occur in the presence of the DPR proteins in cerebellar
post-mortem tissue from C9orf72 ALS patients.
Cerebellum tissue was selected to study the effect of
DPRs on HSR, as previous reports indicate cerebellum
tissue consistently shows a high DPR load [2, 9, 21, 22].
Firstly, we confirmed that DPR species are expressed in
the cerebellum of these C9-ALS patients (Additional
file 4: Figure S2. Next, HSP70 protein levels in human
cerebellum were assessed using western blotting.
C9-ALS patients had significantly higher cerebellar
levels of HSP70 as compared with non-neurological-
disease controls (Fig. 8g+h). Taken together, our data
demonstrate that C9orf72 expansions activate the heat
shock response.
Both C9orf72 and SOD1 ALS zebrafish models ex-
press a hsp70 promotor which drives DsRed protein
production. Cell stress from a variety of insults in-
creases the drive on the hsp70 promotor, and upregula-
tion of the HSP70 protein has been reported in
neurodegenerative disorders such as multiple sclerosis
and, in the present study, ALS [19, 23, 27]. Therefore,
in our ALS zebrafish models, the abundance of DsRed
produced via hsp70 promotor activation is used as a
Fig. 7 C9orf72 model zebrafish display muscle atrophy and motor neuron loss. (a) Representative H&E staining of zebrafish epaxial muscle (body
muscle) myotomes. Scale bar = 50 μm. (b) Frequency distribution of 2.2–2 and NTG myotome sizes. N = 6 individual zebrafish per genotype. (c)
Motor neuron counts show that 2.2–7 zebrafish have significant motor neuron loss compared to NTG. N = 6 individual fish per genotype. (d)
Representative H&E staining of zebrafish spinal cord sections, motor neurons are denoted by arrowheads. Scale bar = 25 μm. Myotome size data
are shown as the frequency of myotome sizes binned into defined ranges, motor neuron count data are mean +/− standard deviation; *P < 0.05,
**P < 0.01, ***P < 0.001 and ****P < 0.0001
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readout of cellular stress. Drugs which reduce cellular
stress, and thereby reduce hsp70 promotor mediated
DsRed production can be identified by treating zebra-
fish with the drug from 2 to 5 dpf, and then measuring
DsRed levels in a fluorescence plate reader [25]. To
date, thousands of compounds have been tested using
this drug screening paradigm in SOD1-ALS zebrafish
models (current authors, data not shown). Ivermectin is
a compound which was identified as one of the most ef-
ficacious drugs in the SOD1 zebrafish screen. In SOD1
Fig. 8 Heat shock stress response activation is induced by C9orf72 expansions. (a) In lysates from both HEK 293 T and N2A cell lines, DsRed levels
are higher in cells transfected with 39 C4G2 pure repeats (Left and middle panel) or 89 C4G2 interrupted repeats (Right panel) compared with
those transfected with only 2 C4G2 repeats. (b) At 5dpf, 2.2–7 zebrafish show significantly higher DsRed fluorescence than 2.2–2 zebrafish. N = 75
2.2–2 and 76 2.2–7 individual zebrafish. (c) At 5dpf, GFP fluorescence is not significantly different between 2.2–7 and 2.2–2 zebrafish. N = 75 2.2–2
and 76 2.2–7 individual zebrafish. (d) In end-stage 2.2–7 zebrafish brains, levels of GFP tagged DPR and DsRed proteins are increased compared
with pre-symptomatic 2.2–7 and NTG. (e) Quantification of GFP tagged DPR protein normalised to tubulin in adult zebrafish brains. N = 3 adult
brains per condition. (f) Quantification of DsRed protein normalised to tubulin in adult zebrafish brains. N = 3 adult brains per condition. (g) In
human cerebellum samples, HSP70 protein levels are higher in C9-ALS patients as compared to non-neurological-disease controls. N = 5 samples
per group. (h) Quantification of HSP70 protein levels normalised to tubulin in human cerebellum. All data are shown as mean +/− standard
deviation; *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
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zebrafish ivermectin treatment reduced the level of
HSR activation (as measured by DsRed fluorescence) to
a similar degree as riluzole (the only disease modifying
treatment currently prescribed for ALS; Fig. 9a). Thus,
in C9orf72 zebrafish ivermectin treatment also resulted
in a significant reduction of HSR activation, and com-
pared with the SOD1 zebrafish screen, the efficacy of
ivermectin was comparable to that of riluzole (Fig. 9b).
Therefore, these data suggest that cross over between
SOD1 and C9orf72 pathology may allow for a single
treatment to be efficacious in both disease forms.
Discussion
We have generated C9orf72-related ALS model zebrafish
which stably express interrupted C4G2 expansions and
exhibit RNA foci and DPR pathology. These zebrafish
accurately recapitulate key aspects of the behavioural,
cognitive, motor defects and reduced survival associated
with C9-ALS/FTD. Additionally, these zebrafish have
been utilised to identify that poly(PR) DPRs form higher
molecular weight species. Furthermore, these C9orf72
zebrafish were used in conjunction with human cell lines
and human post-mortem tissue to identify that C9orf72
expansions activate the HSR. Finally, we identified that
ivermectin treatment reduces cell stress HSR activation
in both SOD1 and C9orf72 zebrafish models. The novel
aspects of the C9orf72 zebrafish model we have gener-
ated here are compared and contrasted to other C9orf72
in vivo models in Table 1.
The zebrafish model presented here lends support to a
gain of function as the toxic mechanism underlying
C9orf72 ALS/FTD. Our data are consistent with several
other studies in animal models showing toxicity mediated
by RNA foci and DPRs [5, 20, 26, 38], including two inde-
pendently generated C9orf72 zebrafish models [18, 28].
Furthermore, our data are consistent with four independ-
ently generated C9orf72 knock-out mice and one
knockout zebrafish model, none of which display any
motor or neurodegenerative changes, arguing against hap-
loinsufficiency as a major contributor to C9orf72 ALS/
FTD [1, 13, 17, 35], (Schmid, Hruscha, Haass, unpub-
lished). In contrast, decreased C9orf72 transcript levels
have been reported in the CNS of G4C2 expansion bearing
patients, and morpholino mediated knockdown of
C9orf72 transcripts have been linked with motor deficits
in zebrafish [6, 11]. However, morpholinos notoriously
have off-target effects and may fail to mimic the pheno-
types observed in stable knockout mutant zebrafish [16].
Thus, the current body of evidence is heavily weighted to-
wards RNA foci/DPR mediated gain of function toxicity in
C9orf72 expansion pathobiology.
Western blotting of zebrafish lysates revealed that mul-
tiple lengths of GFP-tagged DPRs are produced (including
the predicted 48KDa full length peptide) producing a lad-
dered appearance. Both sense and antisense DPR were de-
tected and were produced by both conventional and
RAN-translation. Detection of species of varying MW has
also been reported during RAN-translation of CAG
repeats [42], and during RAN-translation of GGGGCC in
C9-ALS patients [43]. More RAN-translation mediated
bands were detected in 2.2–7 zebrafish compared to 2.2–
2. Interestingly, poly(PR) species were detected at higher
MWs than other DPR species, and it will be important to
investigate whether the tendency of poly(PR)s to form
high MW species is related to the potent in vivo toxicity.
This suggests that RAN-translation blocking agents aimed
specifically at inhibiting HMW poly(PR) formation may
be an important therapeutic avenue to pursue.
The more severe 2.2–7 zebrafish line showed embryonic
onset motor defects and evidence of cognitive abnormal-
ities, thus suggesting that DPR/RNA foci pathology is ad-
versely affecting not only the motor unit, but also
cognitive function; consistent with the spectrum of ALS/
FTD in C9orf72 patients. Assessment of centre avoidance
Fig. 9 Riluzole and Ivermectin modulate HSR in sod1 and C9orf72 zebrafish. (a) Treatment with either 10 μM riluzole or 1 μM ivermectin from 2
to 5 dpf resulted in a significant reduction in DsRed fluorescence in sod1 zebrafish, as compared to DMSO treatment. N = 30 riluzole treated, 23
ivermectin treated and 43 DMSO treated individual zebrafish. (b) Treatment with either 10 μM riluzole or 1 μM ivermectin from 2 to 5
dpf resulted in a significant reduction in DsRed fluorescence in C9orf72 zebrafish (2.2–7 line), as compared to DMSO treatment. N = 34
riluzole treated, 34 ivermectin treated and 33 DMSO treated individual zebrafish. All data are shown as mean +/− standard deviation; *P
< 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
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behaviour indicated that 2.2–7 zebrafish showed an un-
willingness to explore, similar to C9orf72 mice assayed
with the open field paradigm [20]. Early mortality is also
observed in the more severe 2.2–7 zebrafish, indicating
that motor and cognitive defects detectable at the embry-
onic stage later become severe enough to impact upon
survival. Reduction in body weight was observed in 2.2–7
zebrafish at the larval stage, however this later recovered
by adulthood, suggesting that the reduction was due to re-
tardation of the growth process rather than tissue degen-
eration. Indeed, it is possible that slowed growth during
early development of the 2.2–7 line may be due to the ob-
served motor defects reducing access to food.
Swim tunnel performance of the 2.2–7 zebrafish was
significantly poorer than that of their NTG clutchmates
at both 9 and 12 months. Swim tunnel performance is
mainly indicative of the neuromuscular integrity of zeb-
rafish body muscle, however cardiovascular involvement
cannot be ruled out. Small differences in spontaneous
swimming behaviour observed at 9 months became sig-
nificantly different at 12 months, indicating progression
of phenotypic severity. Disease progression was also con-
firmed when the same 2.2–7 swim tunnel tested zebra-
fish displayed clear signs of muscular atrophy and
became unable to swim, necessitating culling. None of
the NTG clutchmates showed this progressive atrophic
phenotype. By 17 months of age over 50% of the 2.2–7
zebrafish required to be culled, however most of the
remaining zebrafish appeared healthy. This indicates a
heterogeneity in progression of phenotype in the 2.2–7
zebrafish, and suggests that genetic, epigenetic or other
factors may modulate the disease phenotype. Indeed, this
phenomenon may explain why the 2.2–2 zebrafish
model present a less severe phenotype. Similar variability
in phenotypic severity has previously been reported in
BAC mice expressing the C9orf72 gene [20].
Abnormal muscle histology was observed in both 2.2–
2 and 2.2–7 zebrafish. Generally muscle fibres were
smaller and more numerous in the transgenic zebrafish,
consistent with atrophy and attempted regeneration. Sig-
nificant motor neuron loss was also observed in 2.2–7
zebrafish and a trend in the same direction was observed
in the 2.2–2 zebrafish. At this point it is not possible to
determine whether the degeneration of the neuromuscu-
lar unit was neurogenic or myogenic in origin, and given
that it is now known that DPR may transmit from cell to
cell there may well be a contribution to toxicity from
both tissues [41].
Previous transient RNA-injection zebrafish models sug-
gest that G4C2 RNA is sufficient to cause activation of
apoptosis and motor axonopathy [18, 36]. It is important
to note that transient RNA-injection models express RNA
in much higher concentrations than would be observed in
stable animal models, therefore the observed pathology is
less likely to be reflective of pathology under physiological
conditions. The RNA-injection zebrafish were not charac-
terised longitudinally as the transgene is only expressed
transiently (typically for 1–3 days). Additionally, an inde-
pendently generated stable zebrafish model has previously
shown that 80 X (G4C2) RNA or poly(GA) DPR expres-
sion leads to pericardial oedema related toxicity at 4 dpf,
but no neurological or motor phenotype was reported at
Table 1 Comparison of Stable C9orf72 stable mouse and zebrafish mutants showing the distinct phenotype and utility of each model
DNA
Construct
Species RNA
Foci
Sense RAN
DPR
Antisense RAN
DPR
ALS phenotype FTD like
phenotype
Stable or
Transient
Phenotype
amenable to
drug screen
Efficacy of
riluzole
Reference
BAC HRE Mouse Yes Yes No Yes Yes Stable No Not tested [14]
BAC HRE Mouse Yes Yes No Yes Yes Stable No Not tested [20]
BAC HRE Mouse Yes Yes No No No Stable No Not tested [29]
BAC HRE Mouse Yes Yes No No No Stable No Not tested [30]
C9 K/O Mouse NA NA NA No No Stable No NA [1, 13, 17, 35]
C9 K/D Zebrafish NA NA NA Axonal growth
defect
No Transient No Not tested [6]
C9 K/O Zebrafish NA NA NA No No Stable No NA [34]; (Schmid,
Hruscha, Haass,
unpublished)
C9 HRE Zebrafish Yes No No No (Mild cardiac
phenotype)
No Stable No Not tested [28]
C9-ATG GA Zebrafish Yes No No No (Severe cardiac
phenotype)
No Stable No (lethal) Not tested [28]
C9 -ATG HRE Zebrafish Yes Yes Yes Yes Yes Stable Yes Yes Current
manuscript
NA Not applicable, K/O Knockout, K/D Knockdown, Grey boxes represents the features that represent similarity to human ALS/FTD or utility in the high throughput
screening of novel therapeutics
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any time point [28]. In contrast, over a comparable time
period (5 dpf), the zebrafish presented here showed both
motor and cognitive dysfunction. Additionally, our zebra-
fish model survived to adulthood and displayed adult-on-
set motor defects which eventually lead to motor neuron
loss and death, thus recapitulating key features of human
ALS/FTD over multiple time points. If model organisms
are to be reliable in terms of the mechanistic insights or
the therapeutic targets they generate, then they must re-
flect disease features accurately. Future models should in-
clude as many disease relevant features as possible until
the exact mechanisms of C9orf72 expansion toxicity are
better understood.
HSP70 protein levels were found to be increased in
C9-ALS patient cerebellar tissue. Consistent with previ-
ous reports, these cerebellum samples were found to
have a substantial DPR load, thus DPRs may mediate
cerebellar HSR activation [2, 9, 21, 22]. Activation of the
HSR as measured by DsRed protein expression under
the control of the hsp70 promotor, was found to be
higher in cells transfected with 39 C4G2 repeats com-
pared to cells transfected with only 2 C4G2 repeats, thus
indicating that C9orf72 expansions of a pathological
length are required for activation of the hsp70 promotor.
Additionally, activation of the HSR as measured by
DsRed protein expression, was higher in 2.2–7 zebrafish
compared with 2.2–2 zebrafish. However, in the same
fish GFP fluorescence was not significantly different, in-
dicating that the total amount of DPR in each of the
2.2-zebrafish lines is equivalent. The reason for a greater
activation of HSR in 2.2–7 could be due to the differen-
tial pattern of DPR expression between the two zebrafish
lines. Variability in transgene copy number is unlikely to
underlie the difference in DsRed production between the
2.2–7 and 2.2–2 zebrafish, as GFP levels between the
two are not significantly different. DsRed and GFP
tagged DPRs also progressively increased in the brains of
end-stage zebrafish, indicating that DsRed production
positively correlates with both DPR production and dis-
ease severity.
Furthermore, C9orf72 and SOD1 ALS zebrafish models
were both validated as good quality drug screening
models by demonstrating reduced cell stress HSR activa-
tion following treatment with riluzole. More importantly,
SOD1 zebrafish identified the compound ivermectin as
reducing cell stress HSR activation, and this finding was
then mirrored in C9orf72 zebrafish, further suggesting
that there is cross over between SOD1 and C9orf72
pathology.
Conclusion
The stable transgenic C9orf72 zebrafish model we have
generated exhibits RAN-translation of DPRs, motor
neuron loss, muscle atrophy, motor impairment,
cognitive abnormalities and reduced adult survival.
Thus, our zebrafish model accurately recapitulates the
more complex aspects of human C9-ALS/FTD pathobi-
ology, which is essential for studying the underlying
mechanisms of ALS/FTD. In addition to all previous in
vivo models of any species, our zebrafish model offers
the unique benefit of being validated for screening of
therapeutic compounds. Using this C9orf72 zebrafish
model we have identified novel insights into the patho-
genesis of C9-ALS/FTD. Specifically, we identified that
poly(PR) DPRs are RAN-translated into higher molecu-
lar weight species compared to other DPRs, which may
explain the greater in vivo toxicity of this DPR species.
Blocking formation of HMW poly(PR) proteins may
therefore represent a novel therapeutic avenue. Add-
itionally, we identified that the heat shock response is
activated by C9orf72 expansions, indicating that protein
chaperone machinery may modify the disease course
through a role in attempted preservation of protein
homeostasis. Finally, by tandem drug screening with
sod1 and C9orf72 zebrafish we identified that ivermectin
may hold therapeutic potential in both of these forms of
ALS. Rapid drug screening and validation of hits in zeb-
rafish models of multiple ALS disease genes will be a
powerful drug-discovery tool going forward.
Additional files
Additional file 1: Sequence of transgene injected to create C9-HRE
transgenic zebrafish. (PDF 120 kb)
Additional file 2: Figure S1. Body mass and body length were not
significantly different at the time of swim tunnel testing. (a) At 9 months
old, body mass of the 2.2–7 and NTG zebrafish tested in the swim tunnel
was not significantly different. N= 12 zebrafish per genotype. (b) At 9 months
old, body length of the 2.2–7 and NTG zebrafish tested in the swim
tunnel was not significantly different. N = 12 zebrafish per genotype.
(c) At 12 months old, body mass of the 2.2–7 and NTG zebrafish
tested in the swim tunnel was not significantly different. N = 13
zebrafish per genotype. (d) At 12 months old, body length of the
2.2–7 and NTG zebrafish tested in the swim tunnel was not significantly
different. N = 13 zebrafish per genotype. All measurements were
carried out ~ 40 min after removal from the swim tunnel (5 min rest,
30 min spontaneous behaviour recording and another 5 min of rest).
(TIF 360 kb)
Additional file 3: End-stage 2.2–7 zebrafish video. (MP4 15919 kb)
Additional file 4: Figure S2. Poly(GA) and poly(GP) DPR proteins are
produced in cerebellum of C9orf72 patients. (a) Dot blots of grey matter
cerebellum samples from n = 5 control, sALS and C9orf72 patients each.
Immunoblotting with an antibody against tubulin reveals mostly even
loading amongst the numerous samples. Immunoblotting with an
antibody against poly(GA) reveals that C9orf72 patients express abundant
poly(GA) DPRs, whereas control and sALS samples do not. And
immunoblotting with an antibody against poly(GP) reveals that
C9orf72 patients express abundant poly(GP) DPRs, whereas control
and sALS samples do not. (b) Quantification showing that in cerebellum
grey matter, significantly higher poly(GA) signal is detected in C9-ALS
samples in comparison to control samples, when normalised to tubulin. (c)
Quantification showing that in cerebellum grey matter, significantly higher
poly(GP) signal is detected in C9-ALS samples in comparison to control
samples, when normalised to tubulin. Con: Control, sALS: sporadic-ALS, C9:
C9orf72-ALS. (TIF 485 kb)
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